Abstract
We have shown previously that activation of endogenously expressed, Gαq/11-coupled P2Y2 nucleotide receptors with UTP reveals an intracellular Ca2+ response to activation of recombinant, Gαi-coupled CXC chemokine receptor 2 (CXCR2) in human embryonic kidney cells. Here, we characterize further this cross talk and demonstrate that phospholipase C (PLC) and inositol 1,4,5-trisphosphate [Ins(1,4,5)P3]-dependent Ca2+ release underlies this potentiation. The putative Ins(1,4,5)P3 receptor antagonist 2-aminoethoxydiphenyl borane reduced the response to CXCR2 activation by interleukin-8, as did sustained inhibition of phosphatidylinositol 4-kinase with wortmannin, suggesting the involvement of phosphoinositides in the potentiation. Against a Li+ block of inositol monophosphatase activity, costimulation of P2Y2 nucleotide receptors and CXCR2 caused phosphoinositide accumulation that was significantly greater than that after activation of P2Y2 nucleotide receptors or CXCR2 alone, and was more than additive. Thus, PLC activity, as well as Ca2+ release, was enhanced. In these cells, agonist-mediated Ca2+ release was incremental in nature, suggesting that a potentiation of Ins(1,4,5)P3 generation in the presence of coactivation of P2Y2 nucleotide receptors and CXCR2 would be sufficient for additional Ca2+ release. Potentiated Ca2+ signaling by CXCR2 was markedly attenuated by expression of either regulator of G protein signaling 2 or the Gβγ-scavenger Gαt1 (transducin α subunit), indicating the involvement of Gαq and Gβγ subunits, respectively.
Footnotes
-
This work was jointly funded by the Biotechnology and Biological Sciences Research Council and AstraZeneca R&D Charnwood (Loughborough, UK).
-
DOI: 10.1124/jpet.103.055632.
-
ABBREVIATIONS: GPCR, G protein-coupled receptor; HEK, human embryonic kidney; HEK-CXCR2, human embryonic kidney cell with stable expression of recombinant human CXCR2; CXCR2, CXC chemokine receptor 2 or IL-8 receptor B; PTX, pertussis toxin; PLC, phospholipase C; Ins(1,4,5)P3, inositol 1,4,5-trisphosphate; AM, acetoxymethyl ester; IL-8, interleukin-8; 2-APB, 2-aminoethoxydiphenyl borane; RGS, regulator of G protein signaling; BSS, balanced salts solution; [Ca2+]i, intracellular Ca2+ concentration; GFP, green fluorescent protein; InsPx, inositol phosphates; PI 3-kinase, phosphatidylinositol 3-kinase; PI 4-kinase, phosphatidylinositol 4-kinase; PIP2, phosphatidylinositol 4,5-bisphosphate; PKC, protein kinase C; DMSO, dimethyl sulfoxide; PP, protein phosphatase; U73122, 1-[6-((17beta-3-methoxyestra-1,3,5(10)-trien-17-yl) amino)hexyl]-1H-pyrrole-2,5-dione; U73343, 1-[6-((17beta-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl]-2,5-pyrrolidinedione.
- Received June 12, 2003.
- Accepted August 8, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|